Roivant Sciences (NASDAQ:ROIV) Stock: Insider Richard Pulik Sells 125,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 125,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $41.20, for a total transaction of $5,150,000.00. Following the completion of the transaction, the chief financial officer owned 269,681 shares of the company’s stock, valued at approximately $11,110,857.20. This trade represents a 31.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Richard Pulik also recently made the following trade(s):

• On Wednesday, November 11th, Richard Pulik sold 175,000 shares of Roivant Sciences stock. The stock was sold at an average price of $41.85, for a total value of $7,323,750.00.

Roivant Sciences Trading Down 1.2%

Shares of NASDAQ ROIV opened at $39.53 on Friday. Roivant Sciences Ltd. has a 12-month low of $19.96 and a 12-month high of $42.50. The business’s fifty day simple moving average is $37.31 and its 200-day simple moving average is $32.25.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. UBS Group set a $55.00 price target on Roivant Sciences in a report on Wednesday, September 9th. Jefferies Financial Group boosted their price objective on Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Citigroup upped their target price on shares of Roivant Sciences from $46.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 24th. Finally, Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.64.

Hedge Funds Weigh In On Roivant Sciences

Several large investors have recently bought and sold shares of the business. Alpine Bank Wealth Management acquired a new stake in Roivant Sciences in the third quarter valued at $25,000. Compass Financial Management LLC purchased a new stake in Roivant Sciences during the 3rd quarter worth about $37,000. Kovack Advisors Inc. purchased a new stake in Roivant Sciences during the 3rd quarter worth about $47,000. Parallel Advisors LLC boosted its position in shares of Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. Finally, Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after acquiring an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Key Headlines Impacting Roivant Sciences

These are some of the ROIV headlines that stood out recently:

• Positive Sentiment: HC Wainwright raised its price target to $48 and maintained a Buy rating. Other recent commentary has pointed to Roivant’s pipeline momentum and possible contributions from clinical progress and drug-launch revenue. HC Wainwright price-target report Pipeline momentum analysis
• Neutral Sentiment: A separate article examines how trial outcomes and drug-launch revenue could affect ROIV, but the provided headline does not report new trial results or specific revenue figures. Trial and drug-launch analysis
• Negative Sentiment: CEO Eric Venker sold 187,943 shares, reducing his stake by 18.81%; the sale was made under a pre-arranged Rule 10b5-1 plan. CFO Richard Pulik sold 125,000 shares on Nov. 10 and another 175,000 on Nov. 11, cutting his position by 44.08%. These substantial insider sales may create near-term pressure on the stock, although the CEO’s transaction was scheduled in advance. CEO SEC filing CFO insider-sales report

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.